Collagen mimetic peptide shows early neuroprotective signals in inherited retinal disease models | OIS Retina 2026

Retinitis pigmentosa (RP) and related inherited retinal diseases (IRDs) span a wide range of causative gene variants, a heterogeneity that has complicated efforts to develop therapies with broad applicability across the category. At the 9th Annual OIS Retina Innovation Summit, held July 14, 2026, in Montréal, Quebec, Stuart Therapeutics presented RP as an indication for its collagen mimetic peptide (CMP) platform for the first time.

A reparative mechanism applied to the posterior segment

Eric Schlumpf, president and CEO of Stuart Therapeutics, described the CMP as a direct reparative agent for helical collagen structures damaged during disease processes. Those structures do more than provide physical support to surrounding cells, he said; they also serve as ligand binding sites for inflammatory modulators and for cell growth and proliferation signals.

"The peptide binds to these damaged locations, restores the structural component of collagen, and flips the cell signaling switch towards inflammatory modulation and improvement in the cellular environment, which happens quite quickly," Schlumpf said.

Preclinical findings in 2 mouse models

The company's first in vivo retinal work used the RD-12 knockout mouse, a model of Leber congenital amaurosis selected specifically because of its aggressive course. Total loss of retinal thickness occurs rapidly in the model, Schlumpf said, which made it a stringent initial test of the peptide.

Treated animals retained retinal thickness with statistical significance compared with controls. Histology showed cells in the posterior retina were improved with treatment, and early visual function testing conducted between intravitreal injections showed an improvement trend in each interval relative to controls. A second study using the RD-10 model confirmed the visual function improvement, Schlumpf said, with additional data expected this month.

Where a gene-agnostic approach fits

Schlumpf was direct about the limits of the mechanism. The peptide is neuroprotective rather than regenerative: "If there has been a complete destruction, death of the nerve cells in the retina, we're not going to make new ones grow back." That positions it as an earlier-stage therapeutic, he said.

Because the approach is not gene-specific, Schlumpf said it could be used in conjunction with other therapies, potentially delaying onset and reducing the impact of an IRD while a patient prepares for or undergoes gene therapy. The company has not taken a position on cell-based therapy, though prior ocular surface work showed benefit to endothelial cells, epithelial cells and nerve cells.

Open development questions

Endpoint selection and trial duration remain undecided and will depend on which gene variants enter the trial, since variants progress at different rates. Those decisions will be made alongside discussions with the FDA. Asked to name the single biggest unanswered question, Schlumpf pointed to indication selection, which he framed as a clinical, regulatory and competitive question at once.